Agilent, ASI Announce Agreement
News Apr 08, 2016
Agilent Technologies Inc. and Applied Spectral Imaging (ASI) have announced they have entered into an agreement to jointly market ASI’s most advanced GenASIs imaging platforms and Agilent’s fluorescence in situ hybridization (FISH) products and solutions, including its Dako Omnis instrument for automated FISH sample processing.
This agreement is expected to bring to pathology labs the components for a fully automated, end-to-end FISH workflow. “We are excited to work with ASI,” said Herman Verrelst, vice president and general manager of Agilent’s Genomics Solutions Division and Clinical Applications Division.
“Difficulty of fluorescence-based molecular analysis has always been a major pain point for our customers. We anticipate that Agilent’s broad portfolio of FISH reagents and instruments, and ASI’s industry-leading computer-aided imaging solutions, will address such critical customer needs and enable laboratories to have a standardized, efficient and high-quality FISH workflow.”
“ASI is proud to partner with Agilent, a global leader in diagnostics that shares our main objective to make patient care better,” said Limor Shiposh, chief executive officer of ASI. “This agreement will position both companies to support customers in all stages of workflows.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.